Affimed Therapeutics Raises Series D
Affimed Therapeutics, a therapeutic TandAb antibody company, has closed a Series D financing round of 15.5 million euros ($20 million). The Series D financing round is led by existing investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed.
9 October 2012•3 mins read
